The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

When investors are attempting to find the best stocks to buy now, they should look beyond factors such as company size (small ...

J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...

Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...

With activist investor Starboard Value holding a seat on Kenvue’s board of directors, the consumer healthcare company is ...

Kenvue’s board of directors are considering ‘a broad range of potential alternatives’ and are hunting for a permanent ...

Kenvue appoints Kirk Perry as interim CEO after Thibaut Mongon's exit and launches strategic review to simplify operations.

Kenvue has five brands that generate over $1 billion in sales—Johnson’s, Neutrogena, Listerine, Tylenol, and Aveeno—as well as a number of brands that generate over $400 million in sales: Nicorette, ...

CEO and board member Thibaut Mongon has stepped down, it said on Monday and named company director Kirk Perry as interim chief executive. The company, which was spun off from Johnson & Johnson ...